- Home
- WTI vs TNXP Comparison
WTI vs TNXP Comparison
Compare WTI & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTI
- TNXP
- Stock Information
- Founded
- WTI 1983
- TNXP 2007
- Country
- WTI United States
- TNXP United States
- Employees
- WTI N/A
- TNXP N/A
- Industry
- WTI Oil & Gas Production
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- WTI Energy
- TNXP Health Care
- Exchange
- WTI Nasdaq
- TNXP Nasdaq
- Market Cap
- WTI 276.1M
- TNXP 272.0M
- IPO Year
- WTI 2005
- TNXP N/A
- Fundamental
- Price
- WTI $1.81
- TNXP $35.48
- Analyst Decision
- WTI
- TNXP Strong Buy
- Analyst Count
- WTI 0
- TNXP 2
- Target Price
- WTI N/A
- TNXP $585.00
- AVG Volume (30 Days)
- WTI 3.9M
- TNXP 729.5K
- Earning Date
- WTI 08-05-2025
- TNXP 08-15-2025
- Dividend Yield
- WTI 2.26%
- TNXP N/A
- EPS Growth
- WTI N/A
- TNXP N/A
- EPS
- WTI N/A
- TNXP N/A
- Revenue
- WTI $514,341,000.00
- TNXP $10,041,000.00
- Revenue This Year
- WTI $3.30
- TNXP $11.66
- Revenue Next Year
- WTI $3.29
- TNXP $793.18
- P/E Ratio
- WTI N/A
- TNXP N/A
- Revenue Growth
- WTI N/A
- TNXP N/A
- 52 Week Low
- WTI $1.09
- TNXP $6.76
- 52 Week High
- WTI $2.84
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- WTI 50.69
- TNXP 52.96
- Support Level
- WTI $1.62
- TNXP $33.71
- Resistance Level
- WTI $1.77
- TNXP $38.13
- Average True Range (ATR)
- WTI 0.18
- TNXP 2.62
- MACD
- WTI -0.05
- TNXP -0.44
- Stochastic Oscillator
- WTI 17.24
- TNXP 61.01
About WTI W&T Offshore Inc.
W&T Offshore Inc is an oil and gas exploration and production company. The company's exploration operations are focused in the Gulf of Mexico, where it drills for oil and gas. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.